ASGCT 2020: editor’s picks

Here are the sessions I’m looking forward to from the American Society of Gene & Cell Therapy virtual Annual Meeting 2020 (May 12-15) agenda.

Like 0 Comment

What is the ASGCT? 

The American Society of Gene & Cell Therapy (ASGCT) brings together scientists, healthcare professionals and patient advocates involved in cell and gene therapy. Despite moving virtual for 2020, their annual meeting is expected to welcome professionals and leaders in the field from around the world to present and discuss their latest developments and ideas.  

This year's meeting is being held online from May 12 until May 15, 2020. Times given below are in EST. Find out more or register for the meeting here>>

What should I look out for at ASGCT 2020? 

ASGCT is a great meeting to get a real feel for where the industry is heading; from workshops on commercialization to focused discussions on manufacturing challenges, if you’re a budding developer of the next block-buster (or even niche-buster), there’s something for you here. How can you demonstrate value to payers and efficacy to regulators? 

  • Clinical Trial Authorization in the EU: Current State and Future Developments (Monday, May 11, 10:15am) - Jan Mueller-Berghaus (European Medicines Agency-Paul-Ehrlich-Institute, Langen, Germany), shares insight into the requirements and considerations for any investigational product. 

  • Valuing Transformative Therapies (Monday, May 11, 1:30pm) - Janet Lynch Lambert (Alliance for Regenerative Medicine, DC, USA) brings her experience to lead a discussion which could provide clarity on the hows and whys of valuation for therapies addressing unmet needs. 

  • Patient Identification/Global Clinical Trial Design (Wednesday, May 13, 8:45am) - Rogerio Vivaldi (Sigilon Therapeutics, MA, USA) discusses the challenges of matching patients to trials and therapeutics, as available cohorts become increasingly reduced as more and more indications qualify as ‘orphan’. 

  • CDMO’s perspectives on process development for viral vectors (Thursday, May 14, 8:52am) - Francesca Vitelli (Lonza, Houston Inc., TX, USA) discusses how to maximize the chance for success in furthering an investigational therapy. 

Other sessions I’ll be hoping to tune in to include clinical trial updates, product case studies and the latest gene editing techniques, and of course one of the pioneers of CAR-T immunotherapy, Carl June (University of Pennsylvania, PA, USA). 

  • Challenges Associated with Long-term Follow-Up of Gene Therapies (Tuesday, May 12, 9:00am) - Anne-Virginie Eggimann (bluebird bio, Inc., MA, USA) discusses potential challenges in pharmacovigilance and post-marketing approval data collection. 

  • George Stamatoyannopoulos Memorial Lecture: Multiplex human T cell genome engineering (Wednesday, May 13, 10:15am) - Carl June has been researching and developing immunotherapies since the field was in its infancy and CTL019, the first gene therapy approved by the FDA, was developed in the June lab. 

  • Clinical Trials Spotlight Symposium (Friday, May 15, 8:00am) - don’t miss this round up of the latest clinical trials, including lentiglobin gene therapies, natural killer T cells and hematopoietic stem cells for indications such as sickle cell disease, metabolic disorders, blastoma and more. 

How can I meet the RegMedNet and Regenerative Medicine team? 

Unfortunately, as ASGCT 2020 has gone virtual, we won’t have a booth for you to visit. However, if you are attending, we’d love to know what you thought of the meeting – why not write a short conference report summarizing your takeaways? If you have other submission enquiries, you can also email me and you can still pick up digital copies of the latest Glossary for Cell & Gene Therapy and Regenerative Medicine

Go to the profile of Freya Leask

Freya Leask

Publisher, Future Science Group

I am the Publisher of RegMedNet, 3DMedNet, RxNet and The Evidence Base, here to help users make the most of the websites and build our expert communities. I am passionate about digital and STM publishing, social media and story-telling. Please get in touch if you have any queries or comments!

No comments yet.